SpringWorks Therapeutics’ Collaboration with GSK Ends
Company Announcements

SpringWorks Therapeutics’ Collaboration with GSK Ends

An update from Springworks Therapeutics (SWTX) is now available.

SpringWorks Therapeutics has been notified that GlaxoSmithKline will terminate their 2022 collaboration agreement regarding joint clinical trials, effective six months after the notice. Despite this, the ongoing trials for a multiple myeloma treatment will continue until completion for the current patients. SpringWorks will still provide support and supply for these trials without incurring any financial penalties from the contract’s end, and retains the rights to further develop and market its products.

For a thorough assessment of SWTX stock, go to TipRanks’ Stock Analysis page.

Related Articles
Carrie WilliamsSWTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TheFlySpringWorks Therapeutics’ ogsiveo shows long-term efficacy in Phase 3 trial
TheFlySpringWorks Therapeutics price target raised to $68 from $64 at JPMorgan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App